Insider · CIK 0001674752
Scott M. Pittman
Files at AURX (Nuo Therapeutics, Inc.). First filing -, latest -.
In brief
Scott M. Pittman files SEC Form 4 as director and 10% owner at AURX (Nuo Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Scott M. Pittman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 28 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Second Restated Warrant (right to buy)derivative | +4,500 | $1.50 | $6,750 | 4,500 | 7 d ago |
| Oct 6, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Prepayment Restated Warrant (right to buy)derivative | +458 | $1.50 | $687 | 458 | 7 d ago |
| Jun 30, 2026 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +40,000 | $1.00 | $40k | 5,440,000 | Jul 2, 2026 |
| Jun 30, 2026 | AURX Nuo Therapeutics, Inc. | FTax withholding Common Stock | -39,604 | $1.01 | $40k | 5,400,396 | Jul 2, 2026 |
| Jun 30, 2026 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -40,000 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jun 29, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Option to purchase common stockderivative | +30,000 | $0.00 | $0 | 30,000 | Jul 2, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Initial Warrant (right to buy)derivative | +30,050 | $1.50 | $45k | 30,050 | Jun 2, 2026 |
| May 29, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Interim Warrant (right to buy)derivative | +17,450 | $1.50 | $26k | 17,450 | Jun 2, 2026 |
| May 29, 2026 | AURX Nuo Therapeutics, Inc. | DDisposition to issuer Second Warrant (right to buy)derivative | -36,750 | $1.50 | $55k | 0 | Jun 2, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Second Warrant (right to buy)derivative | +36,750 | $1.50 | $55k | 0 | Jun 2, 2026 |
| May 29, 2026 | AURX Nuo Therapeutics, Inc. | DDisposition to issuer Prepayment Warrant (right to buy)derivative | -7,516 | $1.50 | $11k | 0 | Jun 2, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Prepayment Warrant (right to buy)derivative | +7,516 | $1.50 | $11k | 0 | Jun 2, 2026 |
| May 29, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Second Restated Warrant (right to buy)derivative | +17,500 | $1.50 | $26k | 0 | Jun 2, 2026 |
| May 29, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Prepayment Restated Warrant (right to buy)derivative | +7,333 | $1.50 | $11k | 0 | Jun 2, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Commitment Warrants (right to buy)derivative | +2,050 | $1.50 | $3,075 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Origination Initial Warrants (right to buy)derivative | +1,333 | $1.50 | $2,000 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Capital Initial Warrants (right to buy)derivative | +26,667 | $1.50 | $40k | 0 | Jan 26, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Origination Second Warrants (right to buy)derivative | +1,750 | $1.50 | $2,625 | 0 | Jan 26, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Capital Second Warrants (right to buy)derivative | +35,000 | $1.50 | $53k | 0 | Jan 26, 2026 |
| Jan 23, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Prepayment Warrants (right to buy)derivative | +7,516 | $1.50 | $11k | 0 | Jan 26, 2026 |
| Jul 30, 2025 | AURX Nuo Therapeutics, Inc. | AGrant or award Common Stock | +3,946 | $1.50 | $5,919 | 5,400,000 | Aug 1, 2025 |
| Nov 15, 2024 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +121,875 | $0.40 | $49k | 5,300,220 | Nov 19, 2024 |
| Nov 15, 2024 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +62,500 | $0.40 | $25k | 5,362,720 | Nov 19, 2024 |
| Nov 15, 2024 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +33,334 | $0.50 | $17k | 5,396,054 | Nov 19, 2024 |
| Aug 9, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to Purchase Common Stockderivative | -121,875 | $0.00 | $0 | 0 | Nov 19, 2024 |
| Dec 31, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to Purchase Common Stockderivative | -62,500 | $0.00 | $0 | 0 | Nov 19, 2024 |
| Mar 4, 2022 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to Purchase Common Stockderivative | -33,334 | $0.00 | $0 | 0 | Nov 19, 2024 |
| Dec 19, 2023 | AURX Nuo Therapeutics, Inc. | AGrant or award Common Stock | +600,000 | $0.50 | $300k | 5,043,345 | Dec 20, 2023 |
Questions about Scott M. Pittman
Answered from the filings on this page, as of the latest one.
Is Scott M. Pittman buying or selling?
Scott M. Pittman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Scott M. Pittman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Scott M. Pittman has 0.
Where does Scott M. Pittman file Form 4?
Scott M. Pittman has filed Form 4 at AURX (Nuo Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.